Vascular endothelial growth factor in eye disease

Area of Science:

• Ophthalmology
• Angiogenesis Research
• Molecular Biology

Background:

• Angiogenic ocular conditions are a primary cause of irreversible vision loss globally.
• Key conditions include retinopathy of prematurity, diabetic retinopathy, and age-related macular degeneration.
• Vascular endothelial growth factor (VEGF) is implicated in the development of these sight-threatening diseases.

Purpose of the Study:

• To elucidate the role of VEGF in the pathogenesis of major angiogenic ocular diseases.
• To discuss the limitations and potential disadvantages of anti-VEGF therapies.
• To explore alternative therapeutic strategies targeting VEGF-related pathways.

Main Methods:

• Review of existing scientific literature on VEGF and ocular angiogenesis.
• Analysis of VEGF's pleiotropic functions in endothelial, neuronal, and glial cells.
• Discussion of clinical implications for anti-VEGF treatments.

Main Results:

• VEGF significantly contributes to angiogenesis in retinopathy of prematurity, diabetic retinopathy, and age-related macular degeneration.
• VEGF's broad biological effects present challenges for targeted inhibition, especially in chronic conditions.
• VEGF influences multiple cellular processes, including proliferation, migration, proteolysis, survival, and vascular permeability.

Conclusions:

• While VEGF is a critical factor in angiogenic eye diseases, its multifaceted roles necessitate careful consideration of therapeutic strategies.
• The pleiotropic nature of VEGF may limit the efficacy and safety of solely inhibiting this factor.
• Targeting other modulators within the VEGF pathway presents a promising avenue for developing more effective treatments for blinding ocular conditions.